719 Phase 1 clinical trial design of ZM008, a first-in-class anti LLT1 antibody is a promising therapy for multiple solid cancers von Ignacio Garcia-Ribas, Maloy Ghosh, Anurag Tiwari, Sanghamitra Bhattacharjee, Yogendra Manjunath, Shalini Kashipathi, Subith Krishna, Ashvini Kumar Dubey, Tirtha Mandal, Soorya Gnanasegaran

Targeting LLT1 as a potential immunotherapy option for cancer patients non-responsive to existing checkpoint therapies in multiple solid tumors von Tirtha Mandal, Soorya Gnanasegaran, Golding Rodrigues, Shalini Kashipathi, Anurag Tiwari, Ashvini Kumar Dubey, Sanghamitra Bhattacharjee, Yogendra Manjunath, Subith Krishna, M. S. Madhusudhan, Maloy Ghosh

Volltext